Literature DB >> 26220265

Galanin receptors as a potential target for neurological disease.

Krista Freimann1, Kaido Kurrikoff2, Ülo Langel3,4.   

Abstract

INTRODUCTION: Galanin is a 29/30 amino acid long neuropeptide that is widely expressed in the brains of many mammals. Galanin exerts its biological activities through three different G protein-coupled receptors, GalR1, GalR2 and GalR3. The widespread distribution of galanin and its receptors in the CNS and the various physiological and pharmacological effects of galanin make the galanin receptors attractive drug targets. AREAS COVERED: This review provides an overview of the role of galanin and its receptors in the CNS, the involvement of the galaninergic system in various neurological diseases and the development of new galanin receptor-specific ligands. EXPERT OPINION: Recent advances and novel approaches in migrating the directions of subtype-selective ligand development and chemical modifications of the peptide backbone highlight the importance of the galanin neurochemical system as a potential target for drug development.

Entities:  

Keywords:  Alzheimer’s disease; depression; epilepsy; galanin; galanin receptors; ligands; neurological disease; neuropeptide

Mesh:

Substances:

Year:  2015        PMID: 26220265     DOI: 10.1517/14728222.2015.1072513

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  8 in total

1.  Opioid-galanin receptor heteromers differentiate the dopaminergic effects of morphine and methadone.

Authors:  Randal A Serafini; Venetia Zachariou
Journal:  J Clin Invest       Date:  2019-05-28       Impact factor: 14.808

2.  Neuronal hypothalamic regulation of body metabolism and bone density is galanin dependent.

Authors:  Anna Idelevich; Kazusa Sato; Kenichi Nagano; Glenn Rowe; Francesca Gori; Roland Baron
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

Review 3.  G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs).

Authors:  Sergi Ferré; Francisco Ciruela; Carmen W Dessauer; Javier González-Maeso; Terence E Hébert; Ralf Jockers; Diomedes E Logothetis; Leonardo Pardo
Journal:  Pharmacol Ther       Date:  2021-09-01       Impact factor: 13.400

4.  Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer.

Authors:  Kiyoshi Misawa; Yuki Misawa; Takeharu Kanazawa; Daiki Mochizuki; Atsushi Imai; Shiori Endo; Thomas E Carey; Hiroyuki Mineta
Journal:  Clin Exp Metastasis       Date:  2015-11-16       Impact factor: 5.150

Review 5.  Trends in GPCR drug discovery: new agents, targets and indications.

Authors:  Alexander S Hauser; Misty M Attwood; Mathias Rask-Andersen; Helgi B Schiöth; David E Gloriam
Journal:  Nat Rev Drug Discov       Date:  2017-10-27       Impact factor: 84.694

6.  An analysis of possible off target effects following CAS9/CRISPR targeted deletions of neuropeptide gene enhancers from the mouse genome.

Authors:  Elizabeth Anne Hay; Abdulla Razak Khalaf; Pietro Marini; Andrew Brown; Karyn Heath; Darrin Sheppard; Alasdair MacKenzie
Journal:  Neuropeptides       Date:  2016-11-04       Impact factor: 3.286

7.  Dataset on Galanin Receptor 3 mutants that improve recombinant receptor expression and stability in an agonist and antagonist bound form.

Authors:  Thao T Ho; Jasmine T Nguyen; Juping Liu; Pawel Stanczak; Aaron A Thompson; Yingzhuo G Yan; Jasmine Chen; Charles K Allerston; Charles L Dillard; Hao Xu; Nicholas J Shoger; Jill S Cameron; Mark E Massari; Kathleen Aertgeerts
Journal:  Data Brief       Date:  2017-05-04

Review 8.  Zinc in the Monoaminergic Theory of Depression: Its Relationship to Neural Plasticity.

Authors:  Urszula Doboszewska; Piotr Wlaź; Gabriel Nowak; Maria Radziwoń-Zaleska; Ranji Cui; Katarzyna Młyniec
Journal:  Neural Plast       Date:  2017-02-19       Impact factor: 3.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.